The 'Big Four' in big pharma

The 'Big Four' in big pharma

When investors hear talk of 'big pharma' it's easy to picture behemoths such as AstraZeneca (AZN) and GlaxoSmithKline (GSK) - stalwarts of the FTSE 100 for years. But, on closer inspection, the four big pharma constituents in that index (five if you count medical equipment company Smith & Nephew (SN.)) have never looked more different.

To continue reading, register today

to enjoy limited access to the following:

  • Daily trading news
  • Funds coverage
  • Features on big investment themes
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now